George Coukos

TIE-2 and VEGFR kinase activities drive immunosuppressive function of TIE-2-expressing monocytes in human breast tumors.

A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside.

Shikonin-loaded antibody-armed nanoparticles for targeted therapy of ovarian cancer.

Overexpression of SMARCE1 is associated with CD8+ T-cell infiltration in early stage ovarian cancer.

Development, optimization, and validation of novel anti-TEM1/CD248 affinity agent for optical imaging in cancer.

T cells bearing a chimeric antigen receptor against prostate-specific membrane antigen mediate vascular disruption and result in tumor regression.

Phage antibody display libraries: a powerful antibody discovery platform for immunotherapy.

Targeting the tumor vasculature to enhance T cell activity.

The Ovarian Cancer Chemokine Landscape Is Conducive to Homing of Vaccine-Primed and CD3/CD28-Costimulated T Cells Prepared for Adoptive Therapy.

Tumor-infiltrating lymphocytes in triple-negative breast cancer: a biomarker for use beyond prognosis?

Angiogenic activity of breast cancer patients' monocytes reverted by combined use of systems modeling and experimental approaches.

Multifunctional mitoxantrone-conjugated magnetic nanosystem for targeted therapy of folate receptor-overexpressing malignant cells.

Personalized approaches to active immunotherapy in cancer.

Whole Tumor Antigen Vaccines: Where Are We?

Erratum to: Multifunctional mitoxantrone-conjugated magnetic nanosystem for targeted therapy of folate receptor-overexpressing malignant cells.

Overexpression of GPC6 and TMEM132D in Early Stage Ovarian Cancer Correlates with CD8+ T-Lymphocyte Infiltration and Increased Patient Survival.

Comprehensive Genomic Characterization of Long Non-coding RNAs across Human Cancers.

Targeting Programmed Cell Death 1 in Ovarian Cancer.

TCR-engineered T cells to treat tumors: Seeing but not touching?

TIE-2-expressing monocytes are lymphangiogenic and associate specifically with lymphatics of human breast cancer.

The Human Vaccines Project: A roadmap for cancer vaccine development.

Mass spectrometry-based antigen discovery for cancer immunotherapy.

Ovarian cancer chemokines may not be a significant barrier during whole tumor antigen dendritic-cell vaccine and adoptive T-cell immunotherapy.

1,2,3-Triazoles as inhibitors of indoleamine 2,3-dioxygenase 2 (IDO2).

Neoantigen-based cancer immunotherapy.

Radiotherapy combination opportunities leveraging immunity for the next oncology practice.

Combine and Conquer: Double CTLA-4 and PD-1 Blockade Combined with Whole Tumor Antigen Vaccine Cooperate to Eradicate Tumors.

Human melanomas and ovarian cancers overexpressing mechanical barrier molecule genes lack immune signatures and have increased patient mortality risk.

Engineering Chimeric Antigen Receptor T-Cells for Racing in Solid Tumors: Don't Forget the Fuel.

TIE-2 expressing monocytes in human cancers.

and cell-based analyses reveal strong divergence between prediction and observation of T-cell-recognized tumor antigen T-cell epitopes.

The T-Cell Receptor Can Bind to the Peptide-Bound Major Histocompatibility Complex and Uncomplexed β-Microglobulin through Distinct Binding Sites.

Identifying biological mechanisms for favorable cancer prognosis using non-hypothesis-driven iterative survival analysis.

Deciphering HLA-I motifs across HLA peptidomes improves neo-antigen predictions and identifies allostery regulating HLA specificity.

Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis.

Local endothelial complement activation reverses endothelial quiescence, enabling t-cell homing, and tumor control during t-cell immunotherapy.

'Hotspots' of Antigen Presentation Revealed by Human Leukocyte Antigen Ligandomics for Neoantigen Prioritization.

High-throughput and Sensitive Immunopeptidomics Platform Reveals Profound Interferonγ-Mediated Remodeling of the Human Leukocyte Antigen (HLA) Ligandome.

Tumour endothelial marker 1/endosialin-mediated targeting of human sarcoma.

Correction to: Characterization of the first fully human anti-TEM1 scFv in models of solid tumor imaging and immunotoxin-based therapy.

Sensitive and frequent identification of high avidity neo-epitope specific CD8 T cells in immunotherapy-naive ovarian cancer.

T cell-induced CSF1 promotes melanoma resistance to PD1 blockade.

Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer.

The C-terminal extension landscape of naturally presented HLA-I ligands.

Consensus guidelines for the use and interpretation of angiogenesis assays.

Label-Free Optofluidic Nanobiosensor Enables Real-Time Analysis of Single-Cell Cytokine Secretion.

CART cells are prone to Fas- and DR5-mediated cell death.

Estimating the Contribution of Proteasomal Spliced Peptides to the HLA-I Ligandome.

Correction to: CART cells are prone to Fas- and DR5-mediated cell death.

Two-Dimensional Label-Free Affinity Analysis of Tumor-Specific CD8 T Cells with a Biomimetic Plasmonic Sensor.

The Length Distribution and Multiple Specificity of Naturally Presented HLA-I Ligands.

Addressing current challenges and future directions in immuno-oncology: expert perspectives from the 2017 NIBIT Foundation Think Tank, Siena, Italy.

A severe case of refractory esophageal stenosis induced by nivolumab and responding to tocilizumab therapy.

Safety and Tolerability of Adoptive Cell Therapy in Cancer.

Tumour-reactive T cell subsets in the microenvironment of ovarian cancer.

Tumor Landscapes: β-Catenin Drives Immune Desertification.

The NAD-Booster Nicotinamide Riboside Potently Stimulates Hematopoiesis through Increased Mitochondrial Clearance.

Computational KIR copy number discovery reveals interaction between inhibitory receptor burden and survival.

Correction: Tumour-reactive T cell subsets in the microenvironment of ovarian cancer.

Going Beyond the Sequences: TCR Binding Patterns at the Service of Cancer Detection.

High-throughput Screening of Human Tumor Antigen-specific CD4 T Cells, Including Neoantigen-reactive T Cells.

Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors.

Mass spectrometry driven exploration reveals nuances of neoepitope-driven tumor rejection.

Targeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function.

Rational combinations of immunotherapy with radiotherapy in ovarian cancer.

A Phase Ib Study of the Combination of Personalized Autologous Dendritic Cell Vaccine, Aspirin, and Standard of Care Adjuvant Chemotherapy Followed by Nivolumab for Resected Pancreatic Adenocarcinoma-A Proof of Antigen Discovery Feasibility in Three Patients.

Integrating SpyCatcher/SpyTag covalent fusion technology into phage display workflows for rapid antibody discovery.

Adenosine mediates functional and metabolic suppression of peripheral and tumor-infiltrating CD8 T cells.

Robust prediction of HLA class II epitopes by deep motif deconvolution of immunopeptidomes.

CD8 Binding of MHC-Peptide Complexes in cis or trans Regulates CD8 T-cell Responses.

Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and no increase in neoantigens with interferon or MEK-inhibitor treatment.

A Phase I/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP-DC) or with tumor lysate (OC-DC) in patients with advanced high-grade ovarian serous carcinoma.

Neutrophils suppress tumor-infiltrating T cells in colon cancer via matrix metalloproteinase-mediated activation of TGFβ.

Analysis of Secondary Structure Biases in Naturally Presented HLA-I Ligands.

Mass spectrometry based immunopeptidomics leads to robust predictions of phosphorylated HLA class I ligands.